Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:

Immunotherapy Web Featured Images 96

Ianalumab add-on therapy in CLL patients receiving ibrutinib

  Feb 03 2021 Tagged CLL, mAbs

Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, discusses a Phase Ib trial (NCT03400176) of ianalumab plus ibrutinib in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib therapy. Ianalumab (VAY736) is an anti-BAFF-R monoclonal antibody that causes antibody-dependent cellular cytotoxicity of B-cells.

Visit website
Immunotherapy Web Featured Images 97

DREAMM-2: Effects of belantamab mafodotin on patient reported outcomes in myelom...

  Feb 03 2021 Tagged MM, mAbs, QoL

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares patient-reported outcomes from the DREAMM-2 study (NCT03525678) of single-agent belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma.

Visit website
Immunotherapy Web Featured Images 98

What are the next steps for CAR-T in myeloma?

  Feb 03 2021 Tagged MM, CAR-T

Sham Mailankody, MBBS, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the future of CAR-T and cellular therapy for multiple myeloma patients. With no currently approved CAR-T therapy for myeloma, he hopes a major advancement will be FDA approval of a BCMA-targeted CAR-T therapy in the near future.

Visit website
Immunotherapy Web Featured Images 99

Magrolimab plus azacitidine in treatment-naïve AML

  Feb 03 2021 Tagged AML, mAbs

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a Phase Ib trial (NCT03248479) of magrolimab, a novel anti-CD47 antibody, plus azacitidine in untreated acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.

Visit website

First-in-human trial of an anti-BCMA ADC for R/R myeloma

  Feb 03 2021 Tagged MM, ADC, anti-BCMA

Meletios Dimopoulos, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of a Phase I, first-in-human dose-escalation trial (NCT03489525) of MEDI2228 in patients with relapsed/refractory (R/R) multiple myeloma.

Visit website

Carfilzomib, Dexamethasone, and Daratumumab Myeloma Treatment Alternative

Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.

Visit website

Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights

  Jan 20 2021 Tagged MM, mAbs, CAR-T

The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of the disease leading to an improvement in patients outcomes.

Visit website

Immunotherapy Inches Forward in Development of Myeloid Malignancies

Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.

Visit website

Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myelo...

Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.

Visit website

Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting.

Visit website